Liquid Sublingual Semaglutide: An Alternative to Semaglutide Injectable

Although developed for diabetes, semaglutide has recently gained popularity due to the public’s discovery of its significant weight loss side effects, with patients flocking to get it. With demand at an unprecedented high, there is a shortage of product in effect and patients are desperate to find an alternative. 

Why is Demand So High for Semaglutide?

By mimicking the hormone GLP-1, which controls appetite, semaglutide may significantly reduce hunger, facilitating notable weight loss and improved blood sugar levels in individuals with type 2 diabetes. Its potential benefits extend beyond weight, potentially lowering the risk of heart disease, making it a multifaceted tool for enhancing overall health.

Overweight and Obesity Statistics in Michigan

34.9% of adults were overweight

30.7% of adults had obesity. 

Source: CDC

Semaglutide is becoming a strategic tool in the battle against weight gain and diabetes, offering hope to those striving for significant health improvements. Traditionally delivered via injections, this powerful medication has now taken a leap forward with the introduction of a liquid sublingual form, courtesy of Health Dimensions Clinical Pharmacy (HDRx). This new method seeks to simplify the lives of patients by offering an alternative to the needle, without suffering from supply issues.

Liquid Sublingual Semaglutide: The New Frontier

At HDRx, we recognize the growing preference among patients for non-injectable forms of medication, particularly when it comes to managing conditions with GLP-1 receptor agonists like Semaglutide. Acknowledging the challenges posed by the traditional injectable routes, HDRx has pioneered the use of a liquid compounded formulation for sublingual administration. 

Utilizing SubMagna™ HMW, a cutting-edge, anhydrous base designed for high molecular weight drugs, we create a sublingual Semaglutide solution that enhances patient compliance and comfort. This innovative approach not only aligns with the preferences of both prescribers and patients who seek alternatives to injections but also those that are exploring new options during the shortage.

SubMagna™ HMW stands out due to its self-emulsifying and permeation-enhancing properties, making it an ideal vehicle for sublingual suspension of Semaglutide. When combined with Semaglutide — sourced from RYBELSUS® tablets — and a patient-preferred flavoring, the result is a simple yet potent sublingual formulation. 

This formulation is designed to form an emulsion upon contact with saliva, improving the solubility and dispersibility of the medication. Moreover, its unique mucoadhesive properties allow for better absorption through mucosal tissues, potentially increasing the drug’s bioavailability and ensuring a more optimal outcome. By leveraging the capabilities of SubMagna™ HMW, HDRx is at the forefront of delivering personalized medication solutions that cater to the specific needs and preferences of our patients, offering them a seamless and more enjoyable treatment experience.

Interested in recommended supplements for semaglutide users?

Prescribers: Semaglutide Rx Order Form

We make it easy to prescribe Semaglutide for your patients. Simply select from our recommended options and fax to our pharmacy.

Choosing HDRx: Your Partner in Health

• Innovation at Its Best: We pride ourselves on offering cutting-edge medications in our state-of-the-art labs. Our liquid sublingual semaglutide is compounded with precision and care, ensuring you receive a top-quality medication.
• Trusted Expertise: Our team of experienced pharmacists specializes in the art of compounding, particularly in transforming semaglutide into a user-friendly sublingual form. You can trust us to provide a personalized medication that meets your unique health needs.
• Unwavering Support: HDRx goes beyond just dispensing medication. We offer a full spectrum of support to both patients and healthcare providers, ensuring a smooth and informed experience from start to finish.
• Ease and Convenience: Accessing your medication has never been easier. HDRx offers direct shipping to your doorstep across Michigan and to several neighboring states, without the hassle of frequent pharmacy visits.

Step into Optimal Health

The advancement of sublingual semaglutide is changing the landscape of weight management and diabetes. If the thought of injections has held you back, this needle-free option might just be the breakthrough you’ve been waiting for.

Health Dimensions Clinical Pharmacy leads the way in providing both injectable and sublingual semaglutide, underlining our dedication to your health and comfort. Whether you are looking for an alternative option or seeking supply during the shortage, HDRx is ready to guide you towards achieving your wellness goals with confidence and ease.

Elevate your patients’ experience with HDRX’s compounded Semaglutide, and be a part of the wellness revolution. We are licensed to ship prescription Semaglutide to MI, OH, IN, IL, IN, WI, and MN.

Related Articles: 

Semaglutide: a new drug for the treatment of obesity
https://pubmed.ncbi.nlm.nih.gov/37879878

Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity
https://pubmed.ncbi.nlm.nih.gov/37605636

Efficacy and safety of semaglutide for weight management: evidence from the STEP program
https://pubmed.ncbi.nlm.nih.gov/36691309

Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5
https://pubmed.ncbi.nlm.nih.gov/36655300

References

1. Amaro A, Sugimoto D, Wharton S. Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Postgrad Med. 2022 Jan;134(sup1):5-17. doi: 10.1080/00325481.2022.2147326. PMID: 36691309.
2. Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Møller DV, Shah SJ, Treppendahl MB, Verma S, Abhayaratna W, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito H, Lelonek M, Melenovsky V, Merkely B, Núñez J, Perna E, Schou M, Senni M, Sharma K, Van der Meer P, von Lewinski D, Wolf D, Petrie MC; STEP-HFpEF Trial Committees and Investigators. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023 Sep 21;389(12):1069-1084. doi: 10.1056/NEJMoa2306963. Epub 2023 Aug 25. PMID: 37622681.
3. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414–1425. doi:10.1001/jama.2021.3224.